Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923513 | 1.00 | GRIK1 (0.35) | GRIK1GRIK2TSHRPTGS1GSTP1 | |
| SCHEMBL23923698 | 0.85 | ALDH1A1 (0.36) | GRIK1GRIK2TSHRPTGS1 | |
| SCHEMBL23923700 | 0.85 | ALDH1A1 (0.36) | GRIK1GRIK2TSHRPTGS1 | |
| SCHEMBL9323590 | 0.84 | TSHR (0.50) | GRIK1GRIK2TSHRPTGS1 | |
| SCHEMBL14856833 | 0.84 | GRIK1 (0.37) | GRIK1GRIK2TSHRPTGS1 | |
| SCHEMBL336388 | 0.84 | GRIK1 (0.37) | GRIK1GRIK2TSHRPTGS1 | |
| SCHEMBL132576 | 0.82 | GRIK1 (0.40) | GRIK1GRIK2TSHRPTGS1 | |
| SCHEMBL1302324 | 0.82 | GRIK1 (0.40) | GRIK1GRIK2TSHRPTGS1 | |
| SCHEMBL23923567 | 0.79 | TSHR (0.37) | GRIK1GRIK2TSHR | |
| SCHEMBL23923568 | 0.79 | TSHR (0.37) | GRIK1GRIK2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527079-B | Method for preparing 2-isopropenyl-5-methyl-4-hexenoic acid and derivative alcohol and carboxylic ester thereof | 信越化学工业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| EP-3901125-B1 | PROCESSES FOR PREPARING 2-ISOPROPENYL-5-METHYL-4-HEXENOIC ACID, 2-ISOPROPENYL-5-METHYL-4-HEXEN-1-OL, AND A CARBOXYLATE ESTER THEREOF | SHINETSU CHEMICAL CO (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11286227-B2 | Processes for preparing 2-isopropenyl-5-methyl-4-hexenoic acid, 2-isopropenyl-5-methyl-4-hexen-1-ol, and a carboxylate ester thereof | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| EP-3901125-A1 | PROCESSES FOR PREPARING 2-ISOPROPENYL-5-METHYL-4-HEXENOIC ACID, 2-ISOPROPENYL-5-METHYL-4-HEXEN-1-OL, AND A CARBOXYLATE ESTER THEREOF | Shin-Etsu Chemical Co., Ltd. (JP) | 2021-10-27 | — | — | EP | disclosed |
| CN-113527079-A | Method for preparing 2-isopropenyl-5-methyl-4-hexenoic acid and derivative alcohol and carboxylic ester thereof | 信越化学工业株式会社 | 2021-10-22 | — | — | CN | disclosed |
| US-20210323902-A1 | PROCESSES FOR PREPARING 2-ISOPROPENYL-5-METHYL-4-HEXENOIC ACID, 2-ISOPROPENYL-5-METHYL-4-HEXEN-1-OL, AND A CARBOXYLATE ESTER THEREOF | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323902-A1 | PROCESSES FOR PREPARING 2-ISOPROPENYL-5-METHYL-4-HEXENOIC ACID, 2-ISOPROPENYL-5-METHYL-4-HEXEN-1-OL, AND A CARBOXYLATE ESTER THEREOF | IGF1R, HPD, IGF2R | GRIK1 13/4885GRIK2 47/4885TSHR 329/4885 |
| US-11286227-B2 | Processes for preparing 2-isopropenyl-5-methyl-4-hexenoic acid, 2-isopropenyl-5-methyl-4-hexen-1-ol, and a carboxylate ester thereof | IGF1R, HPD, IGF2R | GRIK1 13/4885GRIK2 47/4885TSHR 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.